Literature DB >> 8508063

The arterial thrombotic process and emerging drugs for its control.

J M Maraganore1.   

Abstract

Unabated, the arterial thrombotic process continues to be a major challenge in the management of acute coronary artery disease. Pharmacologic and mechanical revascularization therapies, which have proliferated over the last decade, remain impeded by arterial thrombosis and its clinical sequelae. New antithrombotic drugs aimed at specific points in the arterial thrombotic process offer the potential for substantial improvements in the management of coronary artery disease. The use of these agents as a mainstay of patient care is becoming a reality as controlled clinical studies test their safety and potential benefits.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8508063      PMCID: PMC325052     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  22 in total

1.  Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor.

Authors:  W C Kouns; D Kirchhofer; P Hadváry; A Edenhofer; T Weller; G Pfenninger; H R Baumgartner; L K Jennings; B Steiner
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

Review 2.  Platelets and thrombolytic therapy.

Authors:  B S Coller
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

3.  Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.

Authors:  S R Hanson; L A Harker
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 4.  Cofactor proteins in the assembly and expression of blood clotting enzyme complexes.

Authors:  K G Mann; R J Jenny; S Krishnaswamy
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

Review 5.  Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism.

Authors:  R D Rosenberg
Journal:  Am J Med       Date:  1989-09-11       Impact factor: 4.965

6.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

Review 7.  The platelet membrane glycoprotein IIb-IIIa complex.

Authors:  D R Phillips; I F Charo; L V Parise; L A Fitzgerald
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

Review 8.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina.

Authors:  M J Davies; A C Thomas
Journal:  Br Heart J       Date:  1985-04

9.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

10.  Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.

Authors:  M Heras; J H Chesebro; W J Penny; K R Bailey; L Badimon; V Fuster
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.